

## 2016

### 英文論文

1. 2016 Minaga K, Kitano M, Imai H, Miyata T, **Kudo M**: Acute spinal cord infarction after EUS-guided celiac plexus neurolysis. **Gastrointest Endosc** 83:1039-1040, 2016 (IF=6.501).
2. 2016 **Kudo M**: Defect reperfusion imaging with sonazoid®: a breakthrough in hepatocellular carcinoma. **Liver Cancer** 5:1-7, 2016 (IF=7.854).
3. 2016 **Kudo M**: Breakthrough imaging in hepatocellular carcinoma. **Liver Cancer** 5:47-54, 2016 (IF=7.854).
4. 2016 Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Yamao K, Imai H, Sakamoto H, Harwani Y, Chikugo T, Chiba Y, Matsumoto I, Takeyama Y, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for differential diagnosis of pancreatic cysts. **Endoscopy** 48:35-41, 2016 (IF=5.444).
5. 2016 **Kudo M**, Ueshima K, Kubo S, Sakamoto M, Tanaka M, Ikai I, Furuse J, Murakami T, Kadoya M, Kokudo N, Liver Cancer Study Group of Japan: Response evaluation criteria in cancer of the liver (RECICL)(2015 revised version). **Hepatol Res** 46:3-9, 2016 (IF=2.602).
6. 2016 Inoue T, Hyodo T, Korenaga K, Murakami T, Imai Y, Higaki A, Suda T, Takano T, Miyoshi K, Koda M, Tanaka H, Iijima H, Ochi H, Hirooka M, Numata K, **Kudo M**: Kupffer phase image of Sonazoid-enhanced US is useful in predicting a hypervascularization of non-hypervascular hypointense hepatic lesions detected on Gd-EOB-DTPA-enhanced MRI: A multicenter retrospective study. **J Gastroenterol** 51:144-152, 2016 (IF=4.493).
7. 2016 **Kudo M**: Heterogeneity and subclassification of Barcelona Clinic Liver Cancer Stage B. **Liver Cancer** 5:91-96, 2016 (IF=7.854).
8. 2016 Miyata T, Kitano M, Omoto S, Kadosaka K, Kamata K, Imai H, Sakamoto H, Nishida N, Harwani Y, Murakami T, Takeyama Y, Chiba Y, **Kudo M**: Contrast-enhanced harmonic endoscopic ultrasonography for assessment of lymph node metastases in pancreatobiliary carcinoma **World J Gastroenterol** 22:3381-3391, 2016 (IF=3.365).
9. 2016 **Kudo M**, Kanai H: Inclusion of Journal of Medical Ultrasonics in MEDLINE. **J Med Ultrason** 43:163, 2016 (IF=0.455).

10. 2016 Kamata K, Kitano M, Yasukawa S, **Kudo M**, Chiba Y, Ogura T, Higuchi K, Fukutake N, Ashida R, Yamasaki T, Nebiki H, Hirose S, Hoki N, Asada M, Yazumi S, Takaoka M, Okazaki K, Matsuda F, Okabe Y, Yanagisawa A: Histologic diagnosis of pancreatic masses using 25-gauge endoscopic ultrasound needles with and without a core trap: a multicenter randomized trial. **Endoscopy** 48:632-638, 2016 (IF=5.444).
11. 2016 Hagiwara S, Nishida N, **Kudo M**: Reply. **Hepatology** 63:1744-1745, 2016 (IF=13.246).
12. 2016 Geschwind JF, **Kudo M**, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, de Guevara LL, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: TACE treatment in patients with sorafenib-treated unresectable hepatocellular carcinoma in clinical practice: final analysis of GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib). **Radiology** 279:630-640, 2016 (IF=7.296).
13. 2016 Matsui S, Kashida H, **Kudo M**: Gastric perineurioma. **Am J Gastroenterol** 111:453, 2016 (IF=9.566).
14. 2016 Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Matsuda T, Omoto S, Kadosaka K, Yoshikawa T, **Kudo M**: Modified single transluminal gateway transcystic multiple drainage technique for a huge infected walled-off pancreatic necrosis: A case report. **World J Gastroenterol** 22:5132-5136, 2016 (IF=3.365).
15. 2016 Kitano M, Imai H, Kamata K, **Kudo M**: Response. **Gastrointest Endosc** 83:1303, 2016 (IF=6.501).
16. 2016 Kitai S, **Kudo M**, Nishida N, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival benefit of locoregional treatment for hepatocellular carcinoma with advanced liver cirrhosis. **Liver Cancer** 5:175-189, 2016 (IF=7.854).
17. 2016 Minaga K, Kitano M, Sakamoto H, Miyata T, Imai H, Yamao K, Kamata K, Omoto S, Kadosaka K, Sakurai T, Nishida N, Chiba Y, **Kudo M**: Predictors of pain response in patients undergoing endoscopic ultrasound-guided neurolysis for abdominal pain caused by pancreatic cancer. **Ther Adv**

**Gastroenter** 9:483-494, 2016 (IF=3.648).

18. 2016 Kamata K, Kitano M, Omoto S, Kadosaka K, Miyata T, Minaga K, Yamao K, Imai H, **Kudo M**: New endoscopic ultrasonography techniques for pancreaticobiliary diseases. **Ultrasonography** 35:169-179, 2016 (IF=0.000).
19. 2016 Minaga K, Kitano M, Imai H, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Yoshikawa T, **Kudo M**: Urgent endoscopic ultrasound-guided choledochoduodenostomy for acute obstructive suppurative cholangitis-induced sepsis. **World J Gastroenterol** 22:4264-4269, 2016 (IF=3.365).
20. 2016 Abou-Alfa GK, Puig O, Daniele B, **Kudo M**, Merle P, Park JW, Ross P, Peron JM, Ebert O, Chan S, Poon TP, Colombo M, Okusaka T, Ryou BY, Minguez B, Tanaka T, Ohtomo T, Ukrainskyi S, Boisserie F, Rutman O, Chen YC, Xu C, Shochat E, Jukofsky L, Reis B, Chen G, Di Laurenzio L, Lee R, Yen CJ: Randomized Phase II placebo controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. **J Hepatol** 65:289-295, 2016 (IF=12.486).
21. 2016 **Kudo M**, Izumi N, Ichida T, Ku Y, Kokudo N, Sakamoto M, Takayama T, Nakashima O, Matsui O, Matsuyama Y, and the Liver Cancer Study Group of Japan: Report of the 19th follow-up survey of primary liver cancer in Japan. **Hepatol Res** 46:372-390, 2016 (IF=2.602).
22. 2016 **Kudo M**, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JFH, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL: Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study. **Liver Int** 36:1196-1205, 2016 (IF=4.116).
23. 2016 Imai H, Kitano M, Omoto S, Kadosaka K, Kamata K, Miyata T, Yamao K, Sakamoto H, Harwani Y, **Kudo M**: EUS-guided gallbladder drainage for rescue treatment of malignant distal biliary obstruction after unsuccessful ERCP. **Gastrointest Endosc** 84:147-151, 2016 (IF=6.501).
24. 2016 **Kudo M**: Chronic Liver diseases and liver cancer: state-of-the art progress in 2016. **Digest Dis** 34:617-619, 2016 (IF=2.203).

25. 2016 Hagiwara S, Nishida N, Watanabe T, Sakurai T, Ida H, Minami Y, Takita M, Minami T, Iwanishi M, Chishina H, Ueshima K, Komeda Y, Arizumi T, **Kudo M**: Outcome of asunaprevir/daclatasvir combination therapy for chronic liver disease type C. **Digest Dis** 34:620-626, 2016 (IF=2.203).
26. 2016 Nishida N, Kono M, Minami T, Chishina H, Arizumi T, Takita M, Yada N, Ida H, Hagiwara S, Minami Y, Ueshima K, Sakurai T, **Kudo M**: Safety, tolerability, and efficacy of sofosbuvir plus ribavirin in elderly patients infected with hepatitis C virus genotype 2. **Digest Dis** 34:632-639, 2016 (IF=2.203).
27. 2016 Takita M, Iwanishi M, Minami T, Kono M, Chishina K, Arizumi T, Yada N, Hagiwara S, Minami Y, Ida H, Ueshima K, Nishida N, **Kudo M**: Monoethanolamine oleate sclerotherapy for polycystic liver disease. **Digest Dis** 34:654-658, 2016 (IF=2.203).
28. 2016 Chishina H, Hagiwara S, Nishida N, Ueshima K, Sakurai T, Ida H, Minami Y, Takita M, Kono M, Minami T, Iwanishi M, Umehara Y, Watanabe T, Komeda Y, Arizumi T, **Kudo M**: Clinical factors predicting the effect of tolvaptan for refractory ascites in patients with decompensated liver cirrhosis. **Digest Dis** 34:659-664, 2016 (IF=2.203).
29. 2016 Nishida N, **Kudo M**: Clinical significance of epigenetic alterations in human hepatocellular carcinoma and its association with genetic mutations. **Digest Dis** 34:708-713, 2016 (IF=2.203).
30. 2016 Minami Y, Minami T, Chishina H, Kono M, Arizumi T, Takita M, Yada N, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M**: US-US fusion imaging in radiofrequency ablation for liver metastases. **Digest Dis** 34:687-691, 2016 (IF=2.203).
31. 2016 Ogawa C, Minami Y, Morita M, Noda A, Arasawa S, Izuta M, Kubo A, Matsunaka T, Tamaki N, Shibatouge M, **Kudo M**\*: Prediction of embolization area after conventional transcatheter arterial chemoembolization for hepatocellular carcinoma using SYNAPSE VINCENT. **Digest Dis** 34:696-701, 2016 (IF=2.203).
32. 2016 **Kudo M**: Recent trends in the management of hepatocellular carcinoma with special emphasis on treatment with regorafenib and immune checkpoint inhibitors. **Digest Dis** 34:714-730, 2016 (IF=2.203).

33. 2016 Kim SK, Shin MH, Sugimoto K, Kim SR, Imoto S, Kim KI, Taniguchi M, Oh HK, Yano Y, Hayashi T, **Kudo M**: Coffee intake and liver enzyme association in Korean immigrants and Japanese: a comprehensive cross-sectional study. **Digest Dis** 34:665-670, 2016 (IF=2.203).
34. 2016 Yada N, Sakurai T, Minami T, Arizumi T, Takita M, Hagiwara S, Ida H, Ueshima K, Nishida N, **Kudo M**: Prospective risk analysis of hepatocellular carcinoma in patients with chronic hepatitis C by ultrasound strain elastography. **Digest Dis** 34:650-653, 2016 (IF=2.203).
35. 2016 Sugimoto K, Kim SK, Kim SR, Kobayashi M, Kato A, Morimoto E, Imoto S, Kim CW, Tanaka Y, **Kudo M**, Yano Y, Hayashi Y: Efficacy and safety of sofosbuvir plus ribavirin treatment for patients with chronic hepatitis C genotype 2. **Digest Dis** 34:627-631, 2016 (IF=2.203).
36. 2016 Kawasaki T, Hata K, Kinoshita D, Takayama M, Okuda H, Mizuno S, **Kudo M**: Radiofrequency ablation guided by contrast-enhanced sonography versus B-mode sonography for hepatocellular carcinoma after transcatheter arterial chemoembolization. **Digest Dis** 34:692-695, 2016 (IF=2.203).
37. 2016 Iwamoto T, Imai Y, Kogita S, Igura T, Sawai Y, Fukuda K, Yamaguchi Y, Matsumoto Y, Nakahara M, Morimoto O, Seki Y, Ohashi H, Fujita N, **Kudo M**, Takehara T: Comparison of contrast-enhanced ultrasound and Gadolinium-Ethoxybenzyl-Diethylenetriamine Pentaacetic Acid-enhanced MRI for the diagnosis of macroscopic type of hepatocellular carcinoma. **Digest Dis** 34:679-686, 2016 (IF=2.203).
38. 2016 Arizumi T, Ueshima K, Iwanishi M, Minami T, Chishina H, Kono M, Takita M, Kitai S, Inoue T, Yada N, Hagiwara S, Minami Y, Ida H, Sakurai T, Kitano M, Nishida N, **Kudo M**: Validation of Kinki criteria, a modified substaging system, in patients with intermediate stage hepatocellular carcinoma. **Digest Dis** 34:671-678, 2016 (IF=2.203).
39. 2016 Wu T, Wang P, Zhang T, Zheng J, Li JZ, Zeng J, **Kudo M**, Zheng R: Comparison of two-dimensional shear wave elastography and real-time tissue elastography for assessing liver fibrosis in chronic hepatitis B. **Digest Dis** 34:640-649, 2016 (IF=2.203).
40. 2016 Nagai T, Arao T, Nishio K, Matsumoto K, Hagiwara S, Sakurai T, Minami Y,

- Ida H, Ueshima K, Nishida N, Sakai K, Saijo N, Kudo K, Kaneda H, Tamura D, Aomatsu K, Kimura H, Fujita Y, Haji S, **Kudo M**: Impact of tight junction protein ZO-1 and TWIST expression on postoperative survival of patients with hepatocellular carcinoma. **Digest Dis** 34:702-707, 2016 (IF=2.203).
41. 2016 Ramaswami R, Pinato DJ, Kubota K, Ishizuka M, Arizumi T, **Kudo M**, Jang JW, Kim YW, Pirisi M, Allara E, Sharma R: Prognostic sub-classification of intermediate-stage hepatocellular carcinoma: a multicenter cohort study with propensity score analysis. **Med Oncol** 33:114-121, 2016 (IF=2.634).
42. 2016 Minaga K, Kitano M, Imai H, Harwani Y, Yamao K, Kamata K, Miyata T, Omoto S, Kadosaka K, Sakurai T, Nishida N, **Kudo M**: Evaluation of anti-migration properties of biliary covered self-expandable metal stents. **World J Gastroenterol** 22:6917-6924, 2016 (IF=3.365).
43. 2016 **Kudo M**, Izumi N, Sakamoto M, Matsuyama Y, Ichida T, Nakashima O, Matsui O, Ku Y, Kokudo N, Makuuchi M, for the Liver Cancer Study Group of Japan: Survival analysis over 28 years of 173,378 patients with hepatocellular carcinoma in Japan. **Liver Cancer** 5:190-197, 2016 (IF=7.854).
44. 2016 **Kudo M**: Risk of Hepatocellular carcinoma in patients with hepatitis C virus who achieved sustained virological response. **Liver Cancer** 5:155-161, 2016 (IF=7.854).
45. 2016 Cheng AL, Thongprasert S, Lim HY, Sukeepaisarnjaroen W, Yang TS, Wu CC, Chao Y, Chan SL, **Kudo M**, Ikeda M, Kang YK, Pan H, Numata K, Han G, Balsara B, Zhang Y, Rodriguez AM, Zhang Y, Wang Y, Poon RT: Randomized, open-label phase 2 study comparing frontline dovitinib versus sorafenib in patients with advanced hepatocellular carcinoma. **Hepatology** 64:774-784, 2016 (IF=13.246).
46. 2016 Watanabe T, Sadakane Y, Yagama N, Sakurai T, Ezoe H, **Kudo M**, Chiba T, Strober W: Nucleotide-binding oligomerization domain 1 acts in concert with the cholecystokinin receptor agonist, cerulein, to induce IL-33-dependent chronic pancreatitis. **Mucosal Immunol** 9:1234-1249, 2016 (IF=7.478).
47. 2016 Nishida N, Yada N, Hagiwara S, Sakurai T, Kitano M, **Kudo M**: Unique features associated with hepatic oxidative DNA damage and DNA

methylation in non-alcoholic fatty liver disease. **J Gastroen Hepatol** 31:1646-1653, 2016 (IF=3.452).

48. 2016 Makino Y, Imai Y, Igura T, Kogita S, Sawai Y, Fukuda K, Iwamoto T, Okabe J, Takamura M, Fujita N, Hori M, Takehara T, **Kudo M**, Murakami T: Feasibility of extracted-overlay fusion imaging for intraoperative treatment evaluation of radiofrequency ablation for hepatocellular carcinoma. **Liver Cancer** 5:269-279, 2016 (IF=7.854).
49. 2016 Ikeda M, Shimizu S, Sato T, Morimoto M, Kojima Y, Inaba Y, Hagihara A, **Kudo M**, Nakamori S, Kaneko S, Sugimoto R, Tahara T, Ohmura T, Yasui K, Sato K, Ishii H, Furuse J, Okusaka T: Sorafenib plus hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma: Randomized phase II trial. **Ann Oncol** 27: 2090-2096, 2016 (IF=11.855).
50. 2016 **Kudo M**: Regorafenib as second-line systemic therapy may change the treatment strategy and management paradigm for hepatocellular carcinoma. **Liver Cancer** 5:235-244, 2016 (IF=7.854).
51. 2016 Hagiwara S, Nishida N, **Kudo M**: Reply: Hepatocyte damage due to protoporphyrin deposition. **Hepatology** 64:306, 2016 (IF=13.246).
52. 2016 Minaga K, Kitano M, Enoki E, Kashida H, **Kudo M**: Needle-tract seeding on the proximal gastric wall after EUS-guided fine-needle aspiration of a pancreatic mass. **Am J Gastroenterol** 111:1515, 2016 (IF=9.566).
53. 2016 Kim SK, Kim SR, Imoto S, Kim CW, Matsuoka T, Nakashima O, Sasaki M, Kumabe T, **Kudo M**, Fukusato T, Kondo F: Bile duct adenoma in patient with chronic hepatitis C: As a benign neoplasm by pathological and imaging studies. **Pathol Int** 66:640-642, 2016 (IF=1.465).
54. 2016 Kokudo T, Hasegawa K, Matsuyama Y, Takayama T, Izumi N, Kadoya M, **Kudo M**, Ku Y, Sakamoto M, Nakashima O, Kaneko S, Kokudo N: Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion. **J Hepatol** 65:938-943, 2016 (IF=12.486).
55. 2016 Hagiwara S, Nishida N, Chishina H, Ida H, Sakurai T, Komeda Y, Kitano M, **Kudo M**: Cases with refractory ascites and a delayed response to tolvaptan. **Internal Med** 55:3273-3277, 2016 (IF=0.815).

56. 2016 Minaga K, Takenaka M, Miyata T, Ueda Y, Kitano M, **Kudo M**: Through-the-mesh technique after endoscopic ultrasonography-guided hepaticogastrostomy: a novel re-intervention method. **Endoscopy** 48: E369-E370, 2016 (IF=5.444).
57. 2016 Minaga K, Kitano M, Yoshikawa T, Omoto S, Kamata K, Yamao K, **Kudo M**: Hepaticogastrostomy guided by real-time contrast-enhanced harmonic endoscopic ultrasonography: a novel technique. **Endoscopy** 48:E228-229, 2016 (IF=5.444).
58. 2016 **Kudo M**\*, Ikeda M, Takayama T, Numata K, Izumi N, Furuse J, Okusaka T, Kadoya M, Yamashita S, Ito Y, Kokudo N: Safety and efficacy of sorafenib in Japanese patients with hepatocellular carcinoma in clinical practice: a subgroup analysis of GIDEON. **J Gastroenterol** 51:1150-1160, 2016 (IF=4.493).
59. 2016 Marrero JA, **Kudo M**, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R: Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. **J Hepatol** 65:1140-1147, 2016 (IF=12.486).
60. 2016 Pinato DJ, Arizumi T, Jang JW, Allara E, Suppiah P, Smirne C, Tait P, Pai M, Grossi G, Kim YW, Pirisi M, **Kudo M**, Sharma R: Combined sequential use of HAP and ART scores to predict survival outcome and treatment failure following chemoembolization in hepatocellular carcinoma: a multi-center comparative study. **Oncotarget** 7:44705-44718, 2016 (IF=5.168).
61. 2016 Yamao K, Kitano M, Kayahara T, Ishida E, Yamamoto H, Minaga K, Yamashita Y, Nakajima J, Asada M, Okabe Y, Osaki Y, Chiba Y, Imai H, **Kudo M**: Factors predicting through-the-scope gastroduodenal stenting outcomes in patients with gastric outlet obstruction: a large multicenter retrospective study in West Japan. **Gastrointest Endosc** 84:757-763, 2016 (IF=6.501).
62. 2016 Park JO, Ryoo BY, Yen CJ, **Kudo M**, Yang L, Abada PB, Cheng R, Orlando M, Zhu AX, Okusaka T: Second-line ramucirumab therapy for advanced hepatocellular carcinoma (REACH): an East Asian and non-East Asian subgroup analysis **Oncotarget** 7:75482-75491, 2016 (IF=5.168).

63. 2016 **Kudo M**, Trevisani F, Abou-Alfa GK, Rimassa L: Hepatocellular carcinoma: therapeutic guidelines and medical treatment. **Liver Cancer** 6:16-26, 2016 (IF=7.854).
64. 2016 Sakamoto Y, Kokudo N, Matsuyama Y, Sakamoto M, Izumi N, Kadoya M, Kaneko S, Ku Y, **Kudo M**, Takayama T, Nakashima O, Liver Cancer Study Group of Japan: Proposal of a new staging system for intrahepatic cholangiocarcinoma: Analysis of surgical patients from a nationwide survey of the Liver Cancer Study Group of Japan. **Cancer** 122:61-70, 2016 (IF=5.997).